How Dexcom and Abbott are moving beyond diabetes with blood sugar monitoring

Health, Fitness & Food

In this article

According to the Centers for Disease Control and Prevention, more than 37 million people in the U.S. have diabetes. That’s a little more than 11% of the entire population. 

A diabetic’s body doesn’t make enough or any insulin at all. Those with the disease must regularly monitor their blood sugar. This has been traditionally done with glucometers, which diabetics use to prick their fingers over and over again for drops of blood. But over the last decade, technology like continuous glucose monitoring has been on the rise. 

Abbott and Dexcom are the two most dominant players in the space. Both companies have seen increased growth. 

The technology is also being marketed by several health and wellness apps as many companies see benefits for those who don’t have diabetes.

CNBC spoke with both Abbott and Dexcom about the technology inside continuous glucose monitors and how they see it expanding.

Watch the video to learn more.

Products You May Like

Articles You May Like

23andMe CEO Anne Wojcicki considers taking company private
Most doses of Eli Lilly’s Zepbound, Mounjaro in short supply through June, FDA says 
Angel Reese Is Heading to the WNBA — but She Might Be Hanging Up Her Crown
Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
“The Tortured Poets Department” Is Cathartic as Hell — Experts Explain Why

Leave a Reply

Your email address will not be published. Required fields are marked *